April 26, 2024 7:55am

Waiting for PCE, PE, CORE and UN of Michigan inflation-oriented reports

News: The FDA approved Pfizer’s (PFE +$0.23 or +0.91%) treatment for a genetic bleeding disorder, its first-ever gene therapy -- Beqvez, for adults with moderate to severe hemophilia B to win clearance in the U.S. PFE’s treatment will be available by prescription to eligible patients this quarter and has a hefty $3.5 million price tag before insurance and other rebates.

It's a daunting task to understand risk, seeing the unforeseen; on the basis of my own “rules”, I set-up my own “warning analysis” which isn’t machine oriented! 

We crave explanations because they give us an illusion of control.

Never leave an investor uninformed!

 

Remember that overnight and pre-open actions’ futures and global markets doesn't necessarily translate into actual trading in the today’s market session.

Framing the main takeaway … pricing, volume and volatility; it also includes what happened or will happen beyond the headline which shapes today’s potential sector response as seen by RMi.

 

Friday: The pre-open Dow futures are UP +0.13% or (+44 points), the S&P futures are UP +0.78% or (+39 points) as the Nasdaq futures are UP +1.07% or (+187 points)

Futures are positive on Friday, April 26, 2024

European markets were higher,

Asia Pacific markets were mixed as Australia was down

 

Henry’omics:

We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies …

Thursday’s sell-off was triggered by new U.S. economic data that showed a sharp slowdown in growth and pointed to persistent inflation.

Thursday: The Dow closed DOWN -375.12 points or -0.98%, the S&P closed DOWN -23.21 points or -0.46% while the Nasdaq closed DOWN -100.99 points or -0.64%

Economic Data Docket: Friday’s economic data …

  • Personal income, month-over-month, March (+0.5% expected, +0.3% previously);
  • Personal spending, month-over-month, March (+0.6% expected, +0.8% previously);
  • PCE inflation, month-over-month, March (+0.3% expected, +0.3% previously);
  • PCE inflation, year-over-year, March (+2.6% expected, +2.5% previously);
  • "Core" PCE, month-over-month, March (+0.3% expected, +0.3% previously);
  • "Core" PCE, year-over-year, March (+2.7% expected; +2.8% previously);
  • University of Michigan consumer sentiment, April, final reading (77.9 expected, 77.9 previously)

 

Thursday night’s RegMed Investors (RMi) Closing Bell: “hammered. Expectation falls short; watching-out below as contractionary GDP number and 1st sector earnings released.” … https://www.regmedinvestors.com/articles/13434   

 

Q2/24:  April - 15 negative and 4 positive closes

Q1/24:

  • March – 8 positive and 12 negative closes
  • February – 1 market holiday, 11 positive and 9 negative closes
  • January: 2 holidays, 11 negative and 8 positive closes

 

Companies in my headlights – It’s your decision; I provide ideas and context:

I post about “indication intelligence” devoting my time to collection and analysis of information to assist investors with insight into sector vulnerabilities and strengths. A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

 

I am passing on forecasting the daily indications is focused on PCE, Personal income, University of Michigan consumer sentiment economic releases today and inflation-oriented “numbers” tomorrow after the aftermarket fluctuated as the pre-open waits for the all-clear alarm, …  it is still a mix of ups, downs and just unknowns.

 

The BOTTOM LINE:  The cell and gene therapy sector is still in play … indexes erased gains and closed down on Thursday following being narrowly mixed on Wednesday after positive closes on Tuesday and Monday.

  • In compiling my indication signals, I draw on logic, historical precedents, specific knowledge of the sector and its practices as to lessons learned.  It’s important for investors to identify and determine which indication is actual performance based.

Q1/24 Reporting Season:

  • MiMedx (MDXG) on 4/30,
  • Alnylam Pharmaceuticals (ALNY), AxoGen (AXGN), Ultragenyx Pharmaceuticals (RARE) and Blueprint Medicine (BPMC) on Thursday, 5/2;
  • Ionis Pharmaceuticals (IONS) and Agenus (AGEN) on Tuesday, 5/7,
  • Vericel (VCEL) on Wednesday, 5/8

 

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”
  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • Never forget, one of my usual lines. “The sector is … still what it is, until it isn’t and even then, it doesn’t seem to be … that is after taking a deep breath and holding it.”
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.